# A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

> **NCT01678105** · PHASE2 · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 21 (actual)

## Conditions studied

- Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
- Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
- Salivary Gland Cancers
- ACC

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01678105
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678105, "A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01678105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*